How much research do you have to support your results?

All of our products are thoroughly validated in-house using clinical outcomes data and we have published multiple peer-reviewed papers demonstrating the efficacy of our predictions (Veterinary Sciences and Veterinary and Comparative Oncology). We have run over 12,000 tests on hematopoietic cells, and over 4,000 canine patients that have benefited from our services. We believe we have more data on canine lymphoma than any other company in the world.

Other Questions

Back to Help Center

Does pet insurance cover ImpriMed?

Most pet insurance plans that cover cancer care will typically cover ImpriMed’s services. Please check with your insurance representative to see if your plan can cover the services.

What type of sample is needed – just aspirates and a typical flow sample?

We need about 10 million cancer cells to run the full chemosensitivity panel so we ask that you conduct an aggressive woodpecker style FNA, poking as many nodes as possible and putting the cells into our proprietary media tubes (ensures we receive live cells), then of course we need a whole blood sample (2mL).

I have a patient with likely lymphoma/leukemia. For a blood sample, can I just submit an EDTA blood tube or do I still use the ImpriMed tubes (and if so, how many tubes and is an additional EDTA blood tube still needed with that)?

If the patient is suspected of leukemia, blood collected in the EDTA tube should be fine. If it is lymphoma, we might need FNA from the affected organ/lymph node. We can suggest FNA in ImpriMed media tube (1) and 2ml of blood sample in an EDTA tube.

Is it wise to eliminate a certain chemotherapy drug based on the test results or should there be other factors that need to be considered in this decision?

We do not recommend using ImpriMed's predictions to rule out treatment options. The company's artificial intelligence is optimized to give high positive predictive value to help you find drugs with the highest likelihood of producing positive clinical outcomes. For the bests results, our predictions should be used in conjunction with expert knowledge from a skilled oncologist.

How does ImpriMed predict drug responses?

Our predictions are made by artificial intelligence (AI) models trained to predict clinical outcomes from patient data inputs. Clinical outcomes collected from oncologists include reports of progressive disease, stable disease, partial response, and complete response. Patient data used as inputs by the AI models include readings from our live-cell drug sensitivity assay, flow cytometry, PARR, and patient information.Models are re-trained periodically to incorporate new data and refine performance.